<DOC>
	<DOCNO>NCT00048737</DOCNO>
	<brief_summary>The goal clinical research study see low intensity chemotherapy give together new drug 90Y Zevalin , follow transplant blood marrow stem cell donor increase length remission patient leukemia lymphoma . The safety treatment also study .</brief_summary>
	<brief_title>Safety Efficacy 90Y Zevalin Nonmyeloablative Transplantation Lymphoid Malignancies</brief_title>
	<detailed_description>Rituxan antibody make human mouse protein . It react certain antigen lymphoma cell cause body 's immune system destroy lymphoma cell . 90Y Zevalin 111In Zevalin murine-based antibody combine radioactive agent also destroy lymphoma cell . Unlike Rituxan , 90Y Zevalin trace regular scanning require indium determine distribution body . Before treatment start , patient physical exam , include blood test urine test . Women able child must negative blood pregnancy test . Bone marrow sample take . For bone marrow sampling , large needle place hipbone numbed . The bone marrow withdrawn needle . Patients chest x-ray , compute tomography ( CT ) scan , EKG , test lung function . Blood test , urine test , bone marrow sampling , x-rays do need track effect transplant . Patients transfusion blood platelet need . Blood test do daily patient hospital . Patients study receive unlabeled antibody form Y2B8 call rituxan vein follow dose 111In Zevalin vein . 111In Zevalin include radioactive agent indium , show patient x-rays scan . The scan show fast drug travel body long drug stay body . Doctors need able see much drug go tumor much go normal organ see safe give 90Y Zevalin outpatient basis . A scan take 48 72 hour 111In Zevalin give . If radiation 111In Zevalin threat normal organ bone marrow , patient may receive 90Y Zevalin . Seven day 111In Zevalin injection , patient receive second dose rituxan follow dose 90Y Zevalin . Patients also receive fludarabine cyclophosphamide daily 3 day . All chemotherapy drug give catheter ( plastic tube ) extend large chest vein . The catheter leave place throughout treatment . When chemotherapy finish , blood stem cell donor give catheter . Granulocyte colony-stimulating factor ( G-CSF GCSF ) , hormone help production blood cell , injected skin day neutrophil count recover blood . Patients receive methotrexate 3 day post transplant tacrolimus 6 month prevent graft versus host disease . All patient complete checkup , include blood urine test 2 3 time first 12 week study . Tumors measure CT MRI gallium scan . Patients ask fill survey quality life issue ( maintain normal routine , family life , social life , pain ) . It take half hour fill survey . A bone marrow sample may take . A test heart function do . Checkups test do every 3 month 1 year every 6 month 4 year . Treatment give hospital M. D. Anderson . Patients need stay hospital 3 4 week . Patients must stay Houston area 100 day transplant . After , patient need return Houston time time blood test , urine test , exams . This investigational study . 90Y-Zevalin approved FDA relapse refractory lymphoma . Its use trial , however , investigational . About 70 patient take part study . All enrol M. D. Anderson .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<mesh_term>Vidarabine</mesh_term>
	<criteria>1 . Patients relapse consider high risk relapse refractory CD20positive Bcell NHL CLL . Patients consider high risk relapse patient achieve complete response ( CR ) frontline chemotherapy , CLL Richter 's CLL high risk chromosomal abnormality . 2 . Measurable disease . 3 . Age 1870 year , expect survival &gt; /= 3 month , performance status 0 2 . 4 . Availability match related donor . 5 . &lt; /+ 50 % bone marrow involvement . 6 . CLL &lt; /+ 10,000 circulate lymphocyte . 7 . Availability match related unrelated donor . 1 . Prior myeloablative therapy radioimmunotherapy . 2 . Prior external beam radiation therapy &gt; 25 % active bone marrow . 3 . Prior therapy 90Y Zevalin Campath . 4 . CNS lymphoma , HIV , HTLV1 positivity , creatinine &gt; 1.6 mg/dl serum bilirubin &gt; 1.5 mg/dl . 5 . Pregnancy lactation . 6 . Symptomatic pulmonary cardiac disease .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>June 2013</verification_date>
	<keyword>Leukemia</keyword>
	<keyword>Lymphoma</keyword>
	<keyword>Lymphoid Malignancy</keyword>
	<keyword>Cyclophosphamide</keyword>
	<keyword>Cytoxan</keyword>
	<keyword>Neosar</keyword>
	<keyword>Fludarabine</keyword>
	<keyword>Fludarabine Phosphate</keyword>
	<keyword>Fludara</keyword>
	<keyword>Rituximab</keyword>
	<keyword>Rituxan</keyword>
	<keyword>Zevalin</keyword>
	<keyword>Indium Zevalin</keyword>
	<keyword>90Y Zevalin</keyword>
	<keyword>CD-20-positive</keyword>
	<keyword>B-cell Lymphoma</keyword>
	<keyword>CD-20-positive B-cell Lymphoma</keyword>
	<keyword>NHL</keyword>
	<keyword>CLL</keyword>
	<keyword>Chronic Lymphocytic Leukemia</keyword>
	<keyword>Allogeneic Stem Cell Transplantation</keyword>
	<keyword>ASCT</keyword>
</DOC>